A similar approach using GlcN-derivatized inhibitors such as benzoyl glucosamine or hydroxyphenyloxopropyl glucosamine aims to block the Leishmania glucose kinases from Leishmania braziliensis for the treatment of leishmaniasis (38) or, for example, carboxybenzyl glucosamine to specifically inhibit the glucokinase and hexokinase from T. cruzi, a pathogen causing Chagas disease (39). This evidence concerns the gene GCK and leishmaniasis.